Tracking “non-content” metadata is an important part of any pharmaceutical submission, yet many drugmakers fail to take an integrated approach to the task according to regulatory expert Kate Wilber.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
